Stoke Therapeutics, Inc. (NASDAQ:STOK) Expected to Earn Q1 2025 Earnings of ($0.59) Per Share

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Wedbush issued their Q1 2025 earnings estimates for Stoke Therapeutics in a research note issued on Wednesday, August 7th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($0.59) for the quarter. Wedbush has a “Outperform” rating and a $17.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.37) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.63) EPS and Q4 2025 earnings at ($0.59) EPS.

A number of other analysts have also recently commented on STOK. Canaccord Genuity Group cut their price target on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, May 7th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $21.40.

Stoke Therapeutics Price Performance

STOK stock traded up $0.28 during trading hours on Thursday, reaching $14.42. The stock had a trading volume of 289,051 shares, compared to its average volume of 856,720. The stock has a market capitalization of $751.57 million, a PE ratio of -5.98 and a beta of 0.87. The stock has a 50-day simple moving average of $14.47 and a 200 day simple moving average of $11.23. Stoke Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. The firm had revenue of $4.83 million during the quarter, compared to analyst estimates of $3.33 million.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $13.75, for a total transaction of $137,500.00. Following the transaction, the insider now directly owns 2,485 shares of the company’s stock, valued at $34,168.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 11.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds have recently bought and sold shares of the business. Quest Partners LLC bought a new position in Stoke Therapeutics during the second quarter worth about $29,000. Nisa Investment Advisors LLC increased its position in Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after acquiring an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Stoke Therapeutics during the second quarter worth about $123,000. State Board of Administration of Florida Retirement System bought a new position in Stoke Therapeutics during the first quarter worth about $141,000. Finally, BNP Paribas Financial Markets increased its position in Stoke Therapeutics by 86.2% during the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after acquiring an additional 6,636 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.